Assembly Concurrent Resolution 56 formally recognizes April 2025 as Parkinson’s Disease Awareness Month in California and catalogs the state and national burden of the disease, recent research milestones, and the development of the state’s disease registry. The text is a findings-heavy, nonbinding resolution: it does not create new regulatory duties, funding streams, or programmatic mandates.
While ceremonial, the resolution spotlights the California Neurodegenerative Disease Registry and recent biomarker validation that researchers cite as potential game-changers. For health systems, researchers, and patient advocates, the measure is a legislative signal that can influence priorities, data access expectations, and outreach activities even though it does not itself appropriate funds or change legal authorities.
At a Glance
What It Does
The resolution proclaims April 2025 as Parkinson’s Disease Awareness Month in California, lists a set of legislative findings about incidence, costs, research activity, and registry development, and directs the Assembly Chief Clerk to transmit copies of the resolution. It makes no regulatory or funding changes.
Who It Affects
People living with Parkinson’s disease, caregivers, research institutions, nonprofit funders, and the California Department of Public Health (which operates the state registry) are the primary audiences. Health systems named in the findings (for example, Kaiser and Stanford) appear as reporting partners in the registry narrative.
Why It Matters
By collecting and publishing official findings about prevalence, economic cost, registry success, and biomarker progress, the Legislature shapes the public record that advocates and agencies cite when seeking funding, research partnerships, or program changes. The resolution elevates the registry as a model and underscores expectations around data-driven research without committing state funding.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
ACR 56 is a concurrent resolution that does not change law or create budgetary commitments; instead it compiles a set of factual findings and uses them to designate April 2025 as Parkinson’s Disease Awareness Month in California. The document walks through the disease’s clinical profile, cites national and state incidence and cost estimates, and highlights gaps in incidence/prevalence data.
It repeatedly frames the resolution as awareness and recognition rather than an instruction to state agencies.
A substantial portion of the text describes the California Parkinson’s Disease Registry (now expanded as the California Neurodegenerative Disease Registry). The resolution recounts the registry’s origin in the 2017 budget, its operational start in 2018, and its partnerships with more than 500 reporting entities and major health systems.
That account emphasizes automated electronic reporting from physician offices into a state-managed database that is later processed and made available to research institutions.The resolution also lists research developments and funding activity, notably the Michael J. Fox Foundation’s long-term investments and the Parkinson’s Progression Markers Initiative (PPMI).
It calls out the April 2023 validation of a Parkinson’s biomarker as a major scientific milestone. Final operative language is brief: the Legislature recognizes the month, and the Chief Clerk must distribute copies for appropriate dissemination.
There are no grant programs, mandate changes, or regulatory directives buried in the text.Taken together, the resolution functions as a legislative spotlight: it consolidates statistics, names institutional players, and legitimizes the registry and recent biomarker work as evidence-based reasons to increase public attention. For professionals, the practical upshot is signaling — not compliance obligations — but such signals often translate quickly into funding requests, changes in research demand, and public messaging campaigns.
The Five Things You Need to Know
The resolution designates April 2025 as Parkinson’s Disease Awareness Month in California and contains no funding or regulatory directives.
It records that the California Parkinson’s Disease Registry was created in the 2017 state budget, became operational in 2018, and has since been expanded into the California Neurodegenerative Disease Registry.
The registry reportedly has formed reporting relationships with more than 500 entities and collects hundreds of thousands of electronic records that flow from physician offices to the State Department of Public Health.
The text cites estimate(s) of economic burden: $52 billion nationally (with $25 billion borne by the federal government) and $5.8 billion annually attributed to Parkinson’s disease in California.
The resolution highlights the Michael J. Fox Foundation’s role, noting long-term funding contributions (including $2 million annually to three universities) and the April 2023 validation of the first biomarker for Parkinson’s disease.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Disease profile, prevalence, costs, and caregiving burden
This collection of findings summarizes clinical features (motor and nonmotor symptoms), national and state prevalence estimates, incidence trends, and economic impacts. Practically, these paragraphs create a legislative record that quantifies burden and frames Parkinson’s as a fast-growing public-health issue — a record advocates can cite in budget requests or testimony even though the findings impose no obligations.
History and scope of the California Neurodegenerative Disease Registry
These clauses trace the registry’s legislative birth in the 2017 budget, its operational status beginning in 2018, and its subsequent expansion. They name concrete mechanics: automatic electronic transmission of patient data from physicians to the State Department of Public Health and subsequent processing for research access. For practitioners this section clarifies the registry’s data flow and positions the registry as a research resource — but it does not change registry governance, data-sharing rules, or privacy safeguards.
Research milestones and private funding highlighted
The resolution lists the Michael J. Fox Foundation’s funding history, its investments in the PPMI study, and the foundation-supported validation of a Parkinson’s biomarker in April 2023. By naming specific universities and dollar figures, the text signals legislative endorsement of those research investments and establishes a public record of private–academic partnerships relevant to future grantmaking and federal/state collaboration.
Official recognition and administrative transmission
The operative text contains two short directives: the Legislature recognizes April 2025 as Parkinson’s Disease Awareness Month, and the Chief Clerk must transmit copies of the resolution to the author for distribution. These actions are ceremonial and administrative; they create public acknowledgement but do not create entitlements, reporting obligations, or budgetary authority.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People living with Parkinson’s disease and their caregivers — the resolution elevates public awareness, which can increase visibility for services, fundraising, and community outreach without changing benefits or service entitlements.
- Research institutions and universities named in the text (e.g., UCSF, UCSD, USC) — the legislative spotlight and cited funding streams can strengthen grant-writing narratives and institutional reputations tied to PPMI participation.
- Nonprofit funders and advocacy groups (for example, the Michael J. Fox Foundation) — the resolution provides a legislative imprimatur that organizations can leverage in public campaigns and to justify continued philanthropic investment.
- California Department of Public Health and the Neurodegenerative Disease Registry — the measure publicly endorses the registry as a model, which can bolster the registry’s standing with research partners and potential funders seeking to support data infrastructure.
Who Bears the Cost
- California Department of Public Health — while the resolution does not allocate money, increased attention tends to drive more data requests and analytic work, creating operational demands that the department may absorb absent new resources.
- Reporting health systems and physician practices — partners in the registry may face ongoing technical and administrative costs to maintain automated reporting and ensure data quality, even if those burdens predate the resolution.
- Researchers and institutions — the profile the resolution creates can raise external expectations for data access and rapid publication, pressuring researchers to accelerate projects without guaranteed funding or expanded infrastructure.
- Legislative staff and nonprofit partners — distributing materials, organizing awareness activities, and responding to constituent inquiries generates modest administrative work that falls on existing staff and volunteers rather than new appropriations.
Key Issues
The Core Tension
The central tension is between symbolic recognition — which raises visibility and can catalyze advocacy — and the absence of concrete policy or funding commitments: the Legislature signals urgency and research progress while leaving governance, privacy safeguards, and financing unanswered, forcing stakeholders to convert attention into real resources without a mandated pathway.
The resolution is primarily symbolic. It compiles statistics, names partners, and celebrates a biomarker validation, but it does not create new authority, appropriations, or regulatory requirements.
That leaves an information gap: the legislative record signals priorities without specifying who will pay for increased data use, research translation, or expanded services. Expect advocates to use this text to support future budget or policy asks; the resolution itself does not oblige the Legislature or state agencies to follow through.
The registry material raises governance questions the resolution does not address. The document emphasizes automated electronic reporting and large-scale data sharing with research institutions but is silent on data-access criteria, patient consent mechanisms, deidentification standards, and long-term stewardship.
As the registry grows and as biomarker-based research advances, tensions will emerge between facilitating research and protecting patient privacy; the resolution affirms the registry’s utility without clarifying those trade-offs. Finally, public citation of specific funding figures and partner institutions may create the perception that funding and research capacity are sufficient; yet the text acknowledges substantial unmet needs and does not identify new funding sources, which could create frustration among stakeholders expecting concrete follow-up.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.